Business
PrimeGen US, Inc. Announces Proposed Business Combination with DT Cloud Star Acquisition Corporation at an Implied Equity Value of Approximately $1.5 Billion to Advance Its Stem Cell Research and Development Efforts
SANTA ANA, Calif., Feb. 4, 2026 /PRNewswire/ -- PrimeGen US, Inc. ("PrimeGen US" or the "Company"), a pioneering biotech company advancing innovative stem
About this update from Dt Cloud Star Acquisition Corporation
[{"type":"text","content":"SANTA ANA, Calif., Feb. 4, 2026 /PRNewswire/ -- PrimeGen US, Inc. (\"PrimeGen US\" or the \"Company\"), a pioneering biotech company advancing innovative stem cell and exosome therapies, today announced it has entered into a definitive business combination agreement dated as of February 2, 2026 (the \"Business Combination Agreement\") with DT Cloud Star Acquisition Corporation (\"DT Cloud Star\"), a publicly traded special purpose acquisition company (Nasdaq: DTSQ). The transaction implies an equity value for PrimeGen US of approximately $1.5 billion and is expected to provide access to the public markets capital, which the combined company intends to use to advance clinical development, regulatory activities, and if approved, potential commercialization of its lead programs.\n \n \n \n \n \n \n \nUpon closing, which is subject to approval by the stockholders of both PrimeGen US and DT Cloud Star, receipt of required regulatory approvals (including compliance with the Hart-Scott-Rodino Antitrust Improvements Act, if applicable), satisfaction of minimum cash conditions (including any applicable minimum cash condition and redemption thresholds), and other customary closing conditions set forth in the Business Combination Agreement, the combined company is expected to operate as PrimeGen US (or a successor entity) and is anticipated to list on the Nasdaq, subject to Nasdaq approval, under a new ticker symbol. The transaction is currently expected to close in the second half of 2026, although there can be no assurance regarding the timing or completion of the transaction.\"We are thrilled to partner with DT Cloud Star to bring PrimeGen US into the public markets at this pivotal moment,\" said Daniel Chiu, Co-CEO and Chairman of PrimeGen US. \"This transaction is expected to enhance our access to capital and resources, supporting the continued development of our stem cell and exosome programs. Our team's scientific focus and innovation position us to further build our presence in the regenerative medicine field.\"PrimeGen US is a regenerative medicine company, leveraging nearly two decades of proprietary stem cell research to develop Triple Activated Mesenchymal Stem Cells (MSCs) as a novel, cell-based treatment for acute liver injury and related critical conditions. The Company's platform has demonstrated in preclinical activity in ...